Abstract
This was a 2-period randomized, crossover study in 8 healthy males to determine the effects of cimetidine (400 mg q.i.d. for 6 days) on the pharmacokinetics and pharmacodynamic effects of the angiotensin II receptor antagonist, losartan (100 mg). Cimetidine increased the AUC for losartan 18% without affecting the AUC for E-3174, the active metabolite of losartan. The increase in plasma renin activity following losartan was not affected by cimetidine (maximum mean increases 12.6 and 12.1 ng Ang I·ml−1·h−1 without and with cimetidine, respectively). These results indicate that cimetidine does not appear to alter the pharmacokinetics or pharmacodynamics of losartan to a clinically significant extent.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Smith RD, Chiu AT, Wong PC, Herblin WF, Timmermans P (1992) Pharmacology of nonpeptide angiotensin II receptor antagonists. Ann Rev Pharmacol Toxicol 32:135–165
Nelson E, Merrill D, Sweet C, Bradstreet T, Panebianco D, Byyny R, Herman T, Lasseter K, Levy B, Lewis G, McMahon FG, Reeves R, Ruff D, Shepherd A, Weidler D, Irvin J (1991) Efficacy and safety of oral MK-954 DuP 753, an angiotensin receptor antagonist, in essential hypertension. J Hypertension 9[Suppl 6]:S468-S469
Weber MA (1992) Clinical experience with the angiotensin II receptor antagonist losartan: a preliminary report. Am J Hypertension 5[Part 2]:247S–251S
Wong P, Price W, Chi A, Duncia J, Carini D, Wexler R, Johnson A, Timmermans P (1990) Nonpeptide angiotensin II receptor antagonists. XI. Pharmacology of EXP3174: an active metabolite of DuP 753, an orally active antihypertensive agent. J Pharmacol Exp Ther 255:211–217
Munafo A, Christen Y, Nussberger J, Shum L, Borland M, Lee R, Waeber B, Biollaz J, Brunner H (1992) Drug concentration-response relationship in normal volunteers after oral administration of losartan, an angiotensin II receptor antagonist. Clin Pharmacol Ther 51:513–521
Stearns RA, Chakravarty PK, Chen R, Chiu SHL (1995) The biotransformation of losartan to its active carboxylic acid metabolite in human liver microsomes: role of CYP2C and CYP3A subfamily members. Drug Metab Dispos 23:207–215
Shinn AF (1992) Clinical relevance of cimetidine drug interactions. Drug Safety 7:245–267
Van Harten J, et al (1988) Pharmacokinetics and hemodynamic effects of nisoldipine and its interaction with cimetidine. Clin Pharmacol Ther 43:332–341
Schwartz JB, Upton RA, Lin ET, Williams RL, Benet LZ (1988) Effect of cimetidine or ranitidine administration on nifedipine pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 43 (6):673–680
Coleman MD, et al (1990) The use of cimetidine as a selective inhibitor of dapsone N-hydroxylation in man. Br J Clin Pharmacol 30:767
Goldberg M, Tanaka W, Barchowsky A, Bradstreet T, McCrea J, Lo M-W, McWilliams E, Bjornsson, T (1993) Effects of losartan on blood pressure, plasma renin activity, and angiotensin II in volunteers. Hypertension 21:704–713
Cockcroft JR, Sciberras DG, Goldberg MR, Ritter JM (1993) Comparison of angiotensin-converting enzyme inhibition with angiotensin II receptor antagonism in the human forearm. J Cardiovasc Pharmacol 22:579–584
Goldberg MR, Bradstreet TE, McWilliams EJ, Tanaka WK, Lipert S, Bjornsson TD, Waldman SA, Osborne B, Pivadori L, Lewis G, Blum R, Herman T, Abraham PA, Halstenson CN, Lo M-W, Spector R (1995) Biochemical effects of losartan, a non-peptide angiotensin II receptor antagonist, on the renin-angiotensin-aldosterone system in hypertensive patients. Hypertension 25:37–46
Furtek CI, Lo M-W (1992) Simultaneous determination of a novel angiotensin II receptor blocking agent, losartan, and its metabolite in human plasma and urine by high-performance liquid chromatography. J Chromatogr 573:295–301
Lam FC, Hung CT, Perrier DG (1985) Estimation of variance for harmonic mean half-lives. J Pharm Sci 74:229–231
Jones B, Kenward MG (1989) Design and Analysis of crossover trials. Chapman and Hall, New York, 39–39
Shapiro SS, Wilk MB (1965) An analysis of variance test for normality (complete samples). Biometrika: 591–611. Lea and Febiger, Philadelphia, 315–316
Hollander M, Wolfe DA (1973) Nonparametric statistical methods. Wiley, New York, pp 67–82
Hollander M, Wolfe DA (1973) Nonparametric statistical methods. Wiley, New York, pp 75–78
Hollander M, Wolfe DA (1973) Nonparametric statistical methods. Wiley, New York, pp 78–82
Jones B, Kenward MG (1989) Design and analysis of crossover trials. Chapman and Hall, New York, pp 58–59
Stearns RA, Miller RR, Doss GA, Chakravarty PK, Rosegay A, Gatto GJ, Chiu S-H L (1992) The metabolism of DuP 753, a nonpeptide angiotensin II receptor antagonist, by rat, monkey, and human liver slices. Drug Metab Dispos 20:281–287
Lo M-W, Shahinfar S, Furtek CI, Ritter M, Shaw WC, Gehr T, Sica D, Halstenson C, Keane W (1993) Pharmacokinetics of losartan (MK-954 or DuP 753) in patients with renal insufficiency. Clin Pharmacology Ther 53:160
Gradman A, Arcuri K, Goldberg A, Ikeda L, Nelson E, Snavely D, Sweet C (1995) A randomized, placebo-controlled, double-blind, parallel study of various doses of losartan potassium compared to enalapril maleate in patients with essential hypertension. Hypertension 25:1345–1350
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Goldberg, M.R., Lo, M.W., Bradstreet, T.E. et al. Effects of cimetidine on pharmacokinetics and pharmacodynamics of losartan, an AT1-selective non-peptide angiotensin II receptor antagonist. Eur J Clin Pharmacol 49, 115–119 (1995). https://doi.org/10.1007/BF00192369
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00192369